Biliary Tract Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for biliary tract cancer. 25 active patents protecting 2 drugs from 2+ originators. First major cliff: 2030. Daily refresh.

2
Approved drugs
25
Active US patents
54/100
Avg vulnerability
$200M
Annual revenue covered

Originators in Biliary Tract Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Incyte Corp 15 patents Servier 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating biliary tract cancer. Each bar = one year. Y-axis scaled to peak year (6 patents).

1
30
4
33
3
34
6
35
1
36
4
39
6
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pemazyre
PEMIGATINIB
 Incyte Corp 15 45 $200M 2034-04-17
Tibsovo
IVOSIDENIB
 Servier 10 62 — 2030-06-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11667673 Tibsovo method of use 70 2033-01-18
10653710 Tibsovo method of use 70 2036-10-18
11466004 Pemazyre method of use 70 2039-05-03
11466004 Pemazyre method of use 70 2039-05-03
11466004 Pemazyre method of use 70 2039-05-03
11628162 Pemazyre method of use 70 2040-08-30
11628162 Pemazyre method of use 70 2040-08-30
11628162 Pemazyre method of use 70 2040-08-30
10610125 Tibsovo method of use 68 2030-06-21
10717764 Tibsovo method of use 62 2033-01-18

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9611267 Pemazyre composition of matter 4 2035-01-30
9611267 Pemazyre composition of matter 4 2035-01-30
9611267 Pemazyre composition of matter 4 2035-01-30
12552792 Pemazyre composition of matter 17 2040-10-03
12552792 Pemazyre composition of matter 17 2040-10-03
12552792 Pemazyre composition of matter 17 2040-10-03
10449184 Tibsovo formulation 42 2035-03-13
10980788 Tibsovo method of use 62 2039-06-07
10799490 Tibsovo method of use 62 2035-03-13
9968595 Tibsovo method of use 62 2035-03-13

Related